Ardana granted US Teverelix patent
Edinburgh, UK-based drugmaker Ardana has been granted US patent number 7,098,305, covering the long-acting formulation of its gonadotropin-releasing hormone antagonist, Teverelix.
The patent is subject to a US term extension, which means that it is not due to expire in the USA until April 2023. According to Ardana, his award forms part of its growing intellectual property portfolio around its R&D activities.
Teverelix is Ardana's lead development compound and is in Phase II clinical trials in two indications - prostate cancer and benign prostatic hyperplasia, with Phase I studies ongoing in endometriosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze